Definium Reports Third Phase 3 Win for Fast-Dissolve LSD Therapy
Definium’s DT120 ODT LSD tablet cut GAD anxiety scores 5.1 points vs placebo in Phase 3. Effects started by day 2. FDA filing targeted for 2027.
/ 8 items
#DFTX↓
Definium’s Experimental LSD Drug Delivers Strong Phase 3 Results in Anxiety Trial
Definium’s one-dose anxiety drug cut symptoms for 12 weeks, with mostly mild side effects, offering hope for a new treatment.
Wells Fargo Sees Psychedelics Market Hitting $11 Billion by 2035
Wells Fargo sees a booming psychedelic depression market, with new treatments challenging Spravato and creating big opportunities for biotech firms.
Eli Lilly in Advanced Talks to Acquire AtaiBeckley for Psychedelic Mental Health Portfolio
The deal would boost Lilly’s psychedelic pipeline for treatment-resistant depression.
Breakthrough LSD-Derived Drug DT120 Shows Dramatic Antidepressant Effect in Phase 3 Trial
Definium’s DT120 pill showed strong fast and lasting depression relief in Phase 3, with good safety and big symptom cuts.
Compass Pathways Surges as BTIG Reaffirms Buy Rating and Trump’s Psychedelic Executive Order Sparks Sector Rally
BTIG raises CMPS to Buy, $14 target; stock jumps 42% after Trump boosts psychedelic research funding and faster FDA paths.